Board of Directors

Rory Riggs - Chair

Mr. Riggs is Chairman of the Board of GeneNews. He is the Managing Member of Balfour LLC, an investment management company. Mr. Riggs is the past President of Biomatrix, Inc., a NYSE listed company which successfully developed and marketed one of the leading viscosupplementation products in the United States, Synvisc®, for the treatment of osteoarthritis. Prior to Biomatrix, Mr. Riggs was Chief Executive Officer of RF&P Corporation and was also a Managing Director of PaineWebber Inc. Mr. Riggs holds a B.A. from Middlebury College, Vermont, and an MBA from the Graduate School of Business, Columbia University, New York.

Heiner Dreismann - Lead Director

Dr. Heiner Dreismann is Lead Director and Interim CEO for GeneNews and the former President and CEO of Roche Molecular Systems (RMS), a division of F. Hoffmann-La Roche Ltd. and the company that pioneered molecular diagnostics in the clinical arena. Dr. Dreismann led the introduction of PCR-based tests in Europe as early as 1992 and witnessed first hand the industry growth over the last two decades. During his tenure as CEO, RMS annual sales doubled to US$ 1.0 billion and the portfolio of tests and hardware sales were greatly expanded. Prior to being appointed CEO, Dr. Dreismann held other senior positions within Roche Diagnostics in the areas of Global Business Development, Business Unit Manager for PCR and Microbiology, as well as R&D positions in microbiology and infectious diseases, and in manufacturing.

Dr. Dreismann earned a Master’s Degree in Biology and a PhD in Microbiology/Molecular Biology both from Westfaelische Wilhelms University in Muenster, Germany. Dr. Dreismann joined the GeneNews Board of Directors in 2006 and currently holds positions as Lead Director and Chair of the Company’s Strategy Committee in addition to the interim CEO position.

James Howard-Tripp

Mr. Howard-Tripp is President and CEO of Labopharm Inc., a publicly traded international pharmaceutical company. His career in pharmaceuticals extends over twenty-five years and three continents and includes responsibility for research and development, manufacturing, sales and sales management, marketing management at both the domestic and international level, as well as strategic planning and portfolio management. His business development activities have included acquisitions, mergers, divestitures, licensing, as well as co-development and co-selling agreements. Mr. Howard-Tripp joined Labopharm Inc., an international pharmaceutical company, as Executive Vice President in March 2000 and assumed the positions of President and Chief Executive Officer in July 2000. From 1996 to 1998 he held several vice presidential positions with Allelix Biopharmaceuticals Inc. and became President and Chief Executive Officer of the company in 1998. He is also a founding member and past-Chairman of the Canadian Health-Care Licensing Association. Mr. Howard-Tripp is currently the chair of GeneNews’ Corporate Governance Committee and a member of the Human Resources and Compensation Committee.

Garth MacRae

Mr. MacRae is a Director of Dundee Corporation, a merchant bank and financial services company, since 1994. Mr. MacRae is a Chartered Accountant, having received his designation in Manitoba in 1957 and has been a member of the Ontario Institute of Chartered Accountants since 1970. In addition to being a Director of GeneNews and of Dundee Corporation, Mr. MacRae is a director of a number of other public and private companies, including young emerging growth companies. In addition, Mr. MacRae has been interim President and CEO of Breakwater Resources Limited since November 2004. Mr. MacRae is currently the chair of GeneNews’ Audit Committee and a member of the Corporate Governance Committee.

Fran Tuttle

Ms. Tuttle joined the GeneNews Board of Directors in April 2008 and is chair of the GeneNews Human Resources and Compensation Committee and a member of the Audit Committee. She is currently the CEO of HX Diagnostics, a rapid diagnostics company for seasonal and infectious disease. Prior to her current role, Ms. Tuttle held roles as CEO of Protedyne Corporation, a venture backed organization developing robotics for molecular diagnostics, a Senior Vice President with Bayer Diagnostics where she was the general manager of the Near Patient Testing business, a $400MM worldwide business focused on point of care testing in hospitals and doctors’ offices and the Senior Vice President for Chiron Corporation’s global Immunodiagnostics division. Ms. Tuttle is a Certified Public Accountant and also earned an MBA degree from Harvard Business School.

Harry Glorikian

Harry Glorikian joined the GeneNews Board of Directors in April 2008 and is a member of the Strategy and the Human Resources and Compensation Committees. He is the Managing Partner of Scientia Advisors, an international management and strategy consulting firm with a concentration in biotechnology and life sciences. Mr. Glorikian’s expertise spans more than two decades within the life sciences and healthcare industry in areas including diagnostics, molecular biology, proteomics, cellular biology and biodefense. Mr. Glorikian earned a Bachelor of Business Administration degree and an MBA degree, both from Boston University.

K. Wayne Marshall

Dr. Wayne Marshall is a Co-Founder and Chief Clinical Scientist of GeneNews. From 2002 until May 2008, Dr. Marshall was President and CEO of the Company. He is currently Vice Chair of the Board of Directors and a member of the Company’s Strategy Committee. Dr. Marshall has extensive clinical experience with osteoarthritis ranging from the earliest stages of cartilage injury and initial onset, to end-stage disease requiring joint replacement. Dr. Marshall has published over 100 basic research and clinical scientific papers and abstracts and has been a consultant to a number of pharmaceutical and biotech companies. Dr. Marshalls’ "bedside-to-bench-to-bedside" expertise provides GeneNews with a unique perspective that bridges the gap between discovery research and the identification and development of clinically relevant, commercially viable products.

He is trained as an orthopaedic surgeon, knee sub-specialist and research scientist. Dr. Marshall received a B.Sc. from Michigan State University (1973), an M.D. from Wayne State University (1977), a Ph.D. in joint neurophysiology from the University of Toronto (1994), and became a Fellow of the Royal College of Surgeons of Canada in 1984.

Choong-Chin Liew

Dr. C.C. Liew, Professor Emeritus at the University of Toronto, is a Co-Founder and Chief Scientist of GeneNews. He is also a member of the Company’s Strategy Committee. Dr. Liew is a pioneer in the emerging field of molecular medicine and recognized internationally as a leader in disease-specific genomics research. He leads the discovery research program at GeneNews and is the inventor of the Company’s award winning platform technology, the Sentinel Principle™. To date, he has published more than 300 original scientific papers, abstracts, and monographs. His 1997 landmark publication in Circulation, a pre-eminent American peer reviewed journal, reported his work in the cardiovascular system. This report is widely acknowledged to represent the most comprehensive analysis of genes expressed in a single human organ.

Dr. Liew was Visiting Professor of Medicine and Founding Director of the Cardiovascular Genome Unit at Brigham and Women's Hospital, Harvard Medical School, and he has received more than a dozen Honorary Professorships at leading academic and medical institutions in China. Dr. Liew was also recognized with one of Malaysia's top awards, a Datukship (DMPN) which was conferred on him by the Governor of Penang in 2007. Dr. Liew earned his B.Sc. in Biology from Nanyang University (1960), and his M.A. in Physiology (1964) and Ph.D. in Pathological Chemistry from the University of Toronto (1967).